ClinicalTrials.gg
RecruitingNCT06958536CHROMA CDUpdated Nov 2, 2026

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

A Phase 2 interventional study of brivekimig and Placebo in Crohn's Disease, sponsored by Sanofi. Recruiting at 78 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 2, 2026Site recruiting status changedEligibility revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Crohn Disease by Sanofi — 4 open to participants now, 4 under way, 2 of them phase 3. Crohn Disease · Sanofi.

Planned enrollment
8th of 14
99 · median 102
Started
2025
with 1 other
Phase 2
7 of 14
1 open now
Registered
10th of 14
by date

Among the 14 studies in Crohn Disease by Sanofi, this one is the 8th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 2, and was the 10th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 14 studies in Crohn Disease by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Crohn Disease by Sanofi, or all of them as a file.
02

Study summary

This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening
  • Confirmed diagnosis of moderate-to-severe CD
  • History of prior exposure to standard treatment and having inadequate response to, loss of response to or intolerance to standard therapy with any of the following compounds: (5-Amino Salicylates (5-ASAs), 6-Mercaptopurine (6-MP), Azathioprine (AZA), Methotrexate (MTX), oral or or advanced therapies (ATs) (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies
  • On stable doses of standard treatments prior to screening (Oral 5-ASA compounds, Oral corticosteroids, AZA, 6-MP, or MTX, or Antibiotics, etc.)
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Exclusion criteria

Exclusion Criteria:

  • Participants with active Ulcerative Colitis (UC), indeterminate colitis, adenomatous colonic polyps not excised, colonic mucosal dysplasia (low- or high-grade dysplasia) or short bowel syndrome
  • Participants with CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement
  • Participants with following ongoing known complications of CD:

    • Any manifestation that might require bowel surgery while enrolled in the study
    • Participant with ostomy or ileoanal pouch
    • Participant diagnosed with conditions that could interfere with drug absorption including but not limited to short bowel syndrome
    • Participant with surgical bowel resection within the past three months prior to screening, or a history of >3 bowel resections
  • History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    Brivekimig Dose Regimen A

    Participants will receive brivekimig dose regimen A

    Drug: brivekimig

  • Experimental
    Brivekimig Dose Regimen B

    Participants will receive brivekimig dose regimen B

    Drug: brivekimig

  • Placebo comparator
    Placebo

    Participants will receive placebo

    Drug: Placebo

Interventions

  • Route of Administration: Subcutaneous

    Also known as: SAR442970

  • DrugPlacebo

    Route of Administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Percentage of participants who achieve endoscopic response at Week 16

    Endoscopic response is defined as decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) \>50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

    Time frame: From Baseline to Week 16

Secondary outcomes

  1. Percentage of participants who achieve clinical remission based on Crohn's Disease Activity Index (CDAI) at Week 16

    CDAI clinical remission is defined as CDAI score \<150. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.

    Time frame: At Week 16

  2. Percentage of participants who achieve PRO-2 (Patient Reported Outcome) clinical remission at Week 16

    PRO-2 clinical remission is defined as using the average daily Stool Frequency (SF) ≤3 and not worse than baseline and average daily AP ≤1 and not worse than baseline.

    Time frame: At Week 16

  3. Percentage of participants who achieve endoscopic remission based on centrally read SES-CD at Week 16

    Endoscopic remission is defined as SES-CD ≤4 and at least 2 point reduction versus baseline and no subscore \>1 in any individual variable based on central reading.

    Time frame: At Week 16

  4. Percentage of participants who achieve both clinical remission based on CDAI score and endoscopic response based on SES- CD at Week 16

    CDAI clinical remission is defined as CDAI score \<150, endoscopic response is defined as a decrease in SES-CD \>50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading.

    Time frame: At Week 16

  5. Percentage of participants who achieve CDAI clinical response at Week 16

    CDAI clinical response is defined as reduction of CDAI ≥100 points from baseline.

    Time frame: At Week 16

  6. Change from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) score

    The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item instrument assessing health-related quality of life in IBD patients across four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Each question evaluates experiences over the previous two weeks on a 7-point Likert scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224, with higher scores indicating better quality of life. Both domain-specific and overall scores can be calculated.

    Time frame: From Baseline to Week 16

  7. Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score

    The FACIT-F questionnaire assesses fatigue associated with anemia through 13 fatigue-related questions. Each item is scored on a 5-point Likert scale (0="not at all" to 4="very much"), with total scores ranging from 0 to 52. High scores represent less fatigue. For Crohn's Disease patients, a 7-10 point improvement on the FACIT-F total score may represent meaningful improvements.

    Time frame: From Baseline to Week 16

  8. On-treatment serum concentrations of brivekimig at predefined timepoints

    Time frame: Up to End of Study (approximately 164 weeks)

  9. Number and percentage of participants with any Treatment Emergent Adverse Events (TEAEs) during induction, maintenance and Long-term Extension (LTE) treatment period

    Time frame: Up to End of Study (approximately 164 weeks)

  10. Number and percentage of participants with any TEAEs during open-label treatment period

    Time frame: Up to Week 52

  11. Incidence of Anti-drug Antibodies (ADAs) over time

    Time frame: Up to End of Study (approximately 164 weeks)

  12. Percentage of participants who achieve endoscopic remission based on centrally read SES-CD at Week 52

    Endoscopic remission is defined as SES-CD ≤4 and at least 2 point reduction versus baseline and no subscore \>1 in any individual variable based on central reading.

    Time frame: At Week 52

  13. Percentage of participants who achieve endoscopic response at Week 52

    Endoscopic response is defined as decrease in SES-CD \>50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading.

    Time frame: At Week 52

07

Study locations

75 of 78 sites recruiting
  • Investigational Site Number: 8400026
    Fairhope, Alabama 36523, United States
    Recruiting
  • Investigational Site Number: 8400024
    Tucson, Arizona 85724, United States
    Recruiting
  • Investigational Site Number: 8400005
    Escondido, California 92025, United States
    Recruiting
  • Investigational Site Number: 8400001
    Lancaster, California 93534, United States
    Recruiting
  • Investigational Site Number: 8400029
    San Diego, California 92108, United States
    Recruiting
  • Investigational Site Number: 8400032
    Colorado Springs, Colorado 80907, United States
    Recruiting
  • Investigational Site Number: 8400017
    Kissimmee, Florida 34741, United States
    Recruiting
  • Investigational Site Number: 8400015
    Lighthouse PT, Florida 33064, United States
    Recruiting
  • Investigational Site Number 8400028
    Miami, Florida 33134, United States
    Recruiting
  • Investigational Site Number: 8400012
    Miami, Florida 33136, United States
    Recruiting
  • Investigational Site Number: 8400007
    Orlando, Florida 32804, United States
    Recruiting
  • Investigational Site Number: 8400011
    Palmetto Bay, Florida 33176, United States
    Recruiting
  • Investigational Site Number: 8400019
    Marietta, Georgia 30060, United States
    Recruiting
  • Investigational Site Number: 8400025
    Iowa City, Iowa 52242, United States
    Recruiting
  • Investigational Site Number: 8400006
    Kansas City, Kansas 66160, United States
    Recruiting
  • Investigational Site Number: 8400022
    Boston, Massachusetts 02115, United States
    Recruiting
  • Investigational Site Number: 8400008
    Wyoming, Michigan 49519, United States
    Recruiting
  • Investigational Site Number: 8400013
    St Louis, Missouri 63110, United States
    Recruiting
  • Investigational Site Number: 8400003
    Chapel Hill, North Carolina 27599, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Investigational Site Number: 8400009
    Harrisburg, Pennsylvania 17110, United States
    Recruiting
  • Investigational Site Number: 8400002
    Fredericksburg, Texas 78229, United States
    Recruiting
  • Investigational Site Number: 8400010
    Houston, Texas 77030, United States
    Recruiting
  • Investigational Site Number: 8400016
    Ogden, Utah 84405, United States
    Recruiting
  • Investigational Site Number: 8400027
    Richmond, Virginia 23249, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Investigational Site Number: 0360002
    Brisbane, Queensland 4101, Australia
    Recruiting
  • Investigational Site Number: 0360004
    Kurralta Park, South Australia 5037, Australia
    Recruiting
  • Investigational Site Number: 0360001
    Footscray, 3011, Australia
    Recruiting
  • Investigational Site Number: 0560001
    Leuven, B-3000, Belgium
    Recruiting
  • Investigational Site Number: 1560003
    Changsha, 410011, China
    Recruiting
  • Investigational Site Number: 1560008
    Changsha, 410013, China
    Recruiting
  • Investigational Site Number: 1560005
    Changzhou, 213003, China
    Recruiting
  • Investigational Site Number: 1560001
    Guangzhou, 510655, China
    Recruiting
  • Investigational Site Number: 1560006
    Hangzhou, 310009, China
    Recruiting
  • Investigational Site Number: 1560004
    Nanchang, 330006, China
    Recruiting
  • Investigational Site Number: 1560002
    Shanghai, 200092, China
    Recruiting
  • Investigational Site Number: 1560007
    Shenyang, 110004, China
    Recruiting
  • Investigational Site Number: 2030002
    Brno, JM 61500, Czechia
    Recruiting
  • Investigational Site Number: 2030003
    Hradec Králové, 50012, Czechia
    Recruiting
  • Investigational Site Number: 2030005
    Slaný, 274 01, Czechia
    Recruiting
  • Investigational Site Number: 2500001
    Montpellier, 34090, France
    Recruiting
  • Investigational Site Number: 2500003
    Nice, 6000, France
    Recruiting
  • Investigational Site Number: 2500004
    Saint-Priest-en-Jarez, 42270, France
    Recruiting
  • Investigational Site Number: 2500002
    Toulouse, 31059, France
    Recruiting
  • Investigational Site Number: 2760002
    Minden, Northwest 32423, Germany
    Recruiting
  • Investigational Site Number: 2760003
    Jena, 07747, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Investigational Site Number: 2760004
    Kiel, 24105, Germany
    Recruiting
  • Investigational Site Number: 2760001
    Ulm, 89081, Germany
    Recruiting
  • Investigational Site Number: 3920007
    Kashiwa, Chiba 277-0871, Japan
    Recruiting
  • Investigational Site Number: 3920005
    Ōita, Oita Prefecture 870-0033, Japan
    Recruiting
  • Investigational Site Number: 3920006
    Hamamatsu, Shizuoka 432-8061, Japan
    Recruiting
  • Investigational Site Number: 3920004
    Bunkyō City, 113-8519, Japan
    Recruiting
  • Investigational Site Number: 3920003
    Hamamatsu, 431-3192, Japan
    Recruiting
  • Investigational Site Number: 3920009
    Hirosaki, 036-8545, Japan
    Recruiting
  • Investigational Site Number: 3920001
    Morioka, 020-8505, Japan
    Recruiting
  • Investigational Site Number: 3920002
    Nishinomiya, 663-8501, Japan
    Recruiting
  • Investigational Site Number: 6160002
    Wroclaw, Lower Silesian Voivodeship 53-149, Poland
    Recruiting
  • Investigational Site Number: 6160001
    Krakow, 31-501, Poland
    Recruiting
  • Investigational Site Number: 6160005
    Lublin, 20-582, Poland
    Recruiting
  • Investigational Site Number: 6160006
    Sopot, 81-756, Poland
    Recruiting
  • Investigational Site Number: 6160008
    Warsaw, 00-189, Poland
    Recruiting
  • Investigational Site Number: 6160003
    Warsaw, 01-783, Poland
    Recruiting
  • Investigational Site Number: 6160010
    Wroclaw, 52-210, Poland
    Recruiting
  • Investigational Site Number: 6160004
    Wroclaw, 54-206, Poland
    Recruiting
  • Investigational Site Number: 7100001
    Cape Town, 7708, South Africa
    Recruiting
  • Investigational Site Number: 7100004
    Durban, 3610, South Africa
    Recruiting
  • Investigational Site Number: 7100003
    Johannesburg, 1619, South Africa
    Recruiting
  • Investigational Site Number: 710002
    Johannesburg, 1820, South Africa
    Recruiting
  • Investigational Site Number: 7100005
    Plumstead, 7800, South Africa
    Recruiting
  • Investigational Site Number: 724004
    Barcelona, 08022, Spain
    Recruiting
  • Investigational Site Number: 7240002
    Madrid, 28003, Spain
    Recruiting
  • Investigational Site Number: 7240001
    Madrid, 28046, Spain
    Recruiting
  • Investigational Site Number: 7240003
    Seville, 41009, Spain
    Recruiting
  • Investigational Site Number: 8260007
    Bury, BL9 7TD, United Kingdom
    Recruiting
  • Investigational Site Number: 8260004
    Cambridge, CB2 0QQ, United Kingdom
    Recruiting
  • Investigational Site Number: 8260009
    Dagenham, RM9 5QP, United Kingdom
    Recruiting
  • Investigational Site Number: 8260005
    London, E11 1NR, United Kingdom
    Recruiting
  • Investigational Site Number: 8260002
    London, HA8 0AD, United Kingdom
    Recruiting
  • Investigational Site Number: 8260001
    London, SE1 7EH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 18 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 6, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Dec 17, 2026
CompletionEst.
Oct 17, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added, 4 sites removed. 3 sites changed recruiting status (3 now withdrawn)
Show 3 sites
  • Investigational Site Number: 8400003 · Chapel Hill, United StatesRecruiting→Withdrawn
  • Investigational Site Number: 2760003 · Jena, GermanyRecruiting→Withdrawn
  • Investigational Site Number: 8400027 · Richmond, United StatesRecruiting→Withdrawn
Show 16 added (4 United States, 4 China, 4 South Africa, 1 France, 1 Poland, 1 Spain, 1 United Kingdom)
  • Investigational Site Number: 8400026 · Fairhope, United States
  • Investigational Site Number: 8400029 · San Diego, United States
  • Investigational Site Number: 8400032 · Colorado Springs, United States
  • Investigational Site Number: 8400010 · Houston, United States
  • Investigational Site Number: 1560003 · Changsha, China
  • Investigational Site Number: 1560005 · Changzhou, China
  • Investigational Site Number: 1560004 · Nanchang, China
  • Investigational Site Number: 1560002 · Shanghai, China
  • Investigational Site Number: 2500004 · Saint-Priest-en-Jarez, France
  • Investigational Site Number: 6160010 · Wroclaw, Poland
  • Investigational Site Number: 7100001 · Cape Town, South Africa
  • Investigational Site Number: 7100004 · Durban, South Africa
  • Investigational Site Number: 710002 · Johannesburg, South Africa
  • Investigational Site Number: 7100005 · Plumstead, South Africa
  • Investigational Site Number: 724004 · Barcelona, Spain
  • Investigational Site Number: 8260009 · Dagenham, United Kingdom
Show 4 removed
  • Investigative Site: 1560003 · Changsha, China
  • Investigative Site: 1560005 · Changzhou, China
  • Investigative Site: 1560004 · Nanchang, China
  • Investigative Site: 1560002 · Shanghai, China
across 2 updates, Oct 15, 2026 – Nov 2, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedHistory of prior exposure to standard treatment and having inadequate response to, loss of response to or intolerance to standard therapy with any of the following compounds: (5-Amino Salicylates (5-ASAs), steroids6-Mercaptopurine (6-MP), immunomodulatorsAzathioprine (AZA), Methotrexate (MTX), oral or antibiotics)corticosteroids or advanced therapies (ATs) (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies
  • EditedOn stable doses of standard treatments prior to screening (Oral 5-ASA compounds, Oral corticosteroids, Azathioprine (AZA), 6-Mercaptopurine (6-MP), or Methotrexate (MTX), or Antibiotics, etc.)
Oct 15, 2026
Interventions
Changed SAR442970→brivekimig. Arm changed SAR442970 Dose Regimen A→Brivekimig Dose Regimen A; SAR442970 Dose Regimen B→Brivekimig Dose Regimen B
Oct 15, 2026
Secondary outcomes
1 edited, 5 removed
What changed in the outcomes
  • EditedOn-treatment serum concentrations of SAR442970brivekimig at predefined timepointsTime frame: Up to End of Study (approximately 164 weeks)
  • RemovedPercentage of participants achieving CDAI clinical remission at Week 52Time frame: At Week 52
  • RemovedPercentage of participants achieving CDAI clinical remission at both Week 16 and at Week 52Time frame: At Week 52
  • RemovedPercentage of participants who achieve endoscopic response at both Week 16 and Week 52Time frame: At Week 52
  • RemovedPercentage of participants who achieve CDAI clinical response at Week 52Time frame: At Week 52
  • RemovedPercentage of participants who achieve both clinical remission based on CDAI score and endoscopic response based on SES- CD at Week 52Time frame: At Week 52
Oct 15, 2026
Title
A Study to Investigate Efficacy and Safety of SAR442970Brivekimig in PatientsParticipants With Crohn's Disease
Oct 15, 2026
Show all 2 updates
  1. Nov 2, 2026
    16 sites added, 4 sites removed. 2 sites changed recruiting status (2 now withdrawn)
    Show 2 sites
    • Investigational Site Number: 8400027 · Richmond, United StatesRecruiting→Withdrawn
    • Investigational Site Number: 2760003 · Jena, GermanyCompleted→Withdrawn
    Show 16 added (4 United States, 4 China, 4 South Africa, 1 France, 1 Poland, 1 Spain, 1 United Kingdom)
    • Investigational Site Number: 8400026 · Fairhope, United States
    • Investigational Site Number: 8400029 · San Diego, United States
    • Investigational Site Number: 8400032 · Colorado Springs, United States
    • Investigational Site Number: 8400010 · Houston, United States
    • Investigational Site Number: 1560003 · Changsha, China
    • Investigational Site Number: 1560005 · Changzhou, China
    • Investigational Site Number: 1560004 · Nanchang, China
    • Investigational Site Number: 1560002 · Shanghai, China
    • Investigational Site Number: 2500004 · Saint-Priest-en-Jarez, France
    • Investigational Site Number: 6160010 · Wroclaw, Poland
    • Investigational Site Number: 7100001 · Cape Town, South Africa
    • Investigational Site Number: 7100004 · Durban, South Africa
    • Investigational Site Number: 710002 · Johannesburg, South Africa
    • Investigational Site Number: 7100005 · Plumstead, South Africa
    • Investigational Site Number: 724004 · Barcelona, Spain
    • Investigational Site Number: 8260009 · Dagenham, United Kingdom
    Show 4 removed
    • Investigative Site: 1560003 · Changsha, China
    • Investigative Site: 1560005 · Changzhou, China
    • Investigative Site: 1560004 · Nanchang, China
    • Investigative Site: 1560002 · Shanghai, China
  2. Oct 15, 2026
    2 sites changed recruiting status (1 now withdrawn, 1 now completed)
    Show 2 sites
    • Investigational Site Number: 8400003 · Chapel Hill, United StatesRecruiting→Withdrawn
    • Investigational Site Number: 2760003 · Jena, GermanyRecruiting→Completed
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedHistory of prior exposure to standard treatment and having inadequate response to, loss of response to or intolerance to standard therapy with any of the following compounds: (5-Amino Salicylates (5-ASAs), steroids6-Mercaptopurine (6-MP), immunomodulatorsAzathioprine (AZA), Methotrexate (MTX), oral or antibiotics)corticosteroids or advanced therapies (ATs) (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies
    • EditedOn stable doses of standard treatments prior to screening (Oral 5-ASA compounds, Oral corticosteroids, Azathioprine (AZA), 6-Mercaptopurine (6-MP), or Methotrexate (MTX), or Antibiotics, etc.)
    Secondary outcomes 1 edited, 5 removed
    What changed in the outcomes
    • EditedOn-treatment serum concentrations of SAR442970brivekimig at predefined timepointsTime frame: Up to End of Study (approximately 164 weeks)
    • RemovedPercentage of participants achieving CDAI clinical remission at Week 52Time frame: At Week 52
    • RemovedPercentage of participants achieving CDAI clinical remission at both Week 16 and at Week 52Time frame: At Week 52
    • RemovedPercentage of participants who achieve endoscopic response at both Week 16 and Week 52Time frame: At Week 52
    • RemovedPercentage of participants who achieve CDAI clinical response at Week 52Time frame: At Week 52
    • RemovedPercentage of participants who achieve both clinical remission based on CDAI score and endoscopic response based on SES- CD at Week 52Time frame: At Week 52
    Interventions Changed SAR442970→brivekimig. Arm changed SAR442970 Dose Regimen A→Brivekimig Dose Regimen A; SAR442970 Dose Regimen B→Brivekimig Dose Regimen B
    Title A Study to Investigate Efficacy and Safety of SAR442970Brivekimig in PatientsParticipants With Crohn's Disease
    + 3 other changes: verification date, description and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06958536
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Jun 3, 2025
Primary completion
Dec 17, 2026 (estimated)
Completion
Oct 17, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. Option 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivekimig

Start the discussion